Brief: Carisma Therapeutics Announces First Patient Dosed In Phase 1 Clinical Trial Of Ct-0525
16/05/2024 12:34
May 16 (Reuters) - Carisma Therapeutics Inc CARM.O :
* CARISMA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
PHASE 1
CLINICAL TRIAL OF CT-0525, A NOVEL HER2-TARGETING CAR-MONOCYTE
* CARISMA THERAPEUTICS INC - INITIAL DATA EXPECTED BY
YEAR-END
2024
Source text for Eikon: ID:nPnr6K3Ra
Further company coverage: CARM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Carisma Therapeutics
See all newsBrief: Carisma Therapeutics & Modernatx Amend Collaboration & And License Agreement - SEC Filing
Carisma Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Carisma Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Carisma Therapeutics And Orthocellix Enter Into Definitive Merger Agreement
Carisma Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary